ABSCI CORP Investing Cash Flow
ABSCI CORP (ABSI) reported Investing Cash Flow of $31.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- ABSCI CORP net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was $24.07M, a 166.27% increase year-over-year.
- ABSCI CORP net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was $7.36M.
- ABSCI CORP net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was $19.55M, a 2.65% increase year-over-year.
- ABSCI CORP net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$63.70M, a 530.24% decline year-over-year.
- ABSCI CORP net cash provided by (used in) investing activities for fiscal 2025 was -$50.16M.
- ABSCI CORP net cash provided by (used in) investing activities for fiscal 2024 was -$41.58M, a 150.74% decline from fiscal 2023.
- ABSCI CORP net cash provided by (used in) investing activities for fiscal 2023 was $81.94M.
- ABSCI CORP net cash provided by (used in) investing activities for fiscal 2022 was -$126.98M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $24.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $31.43M 10-Q · filed 2026-08-11 | $50.98M derived: sum of 3 quarters · filed 2026-08-11 | -$12.72M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $7.36M 10-Q · filed 2026-05-07 | $26.91M derived: sum of 2 quarters · filed 2026-05-07 | -$36.79M derived: sum of 3 quarters · filed 2026-05-07 | -$27.75M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $19.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | -$44.16M derived: sum of 2 quarters · filed 2026-03-24 | -$35.12M derived: sum of 3 quarters · filed 2026-08-11 | -$50.16M 10-K · filed 2026-03-24 |
| 2025-09-30 | -$63.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$54.66M derived: sum of 2 quarters · filed 2026-08-11 | -$69.71M 10-Q · filed 2025-11-12 | -$50.66M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $9.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$6.00M 10-Q · filed 2026-08-11 | $13.04M derived: sum of 3 quarters · filed 2026-08-11 | $27.84M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$15.04M 10-Q · filed 2026-05-07 | $4.00M derived: sum of 2 quarters · filed 2026-05-07 | $18.80M derived: sum of 3 quarters · filed 2026-05-07 | $20.06M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $19.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-24 | $33.85M derived: sum of 2 quarters · filed 2026-03-24 | $35.10M derived: sum of 3 quarters · filed 2026-03-24 | -$41.58M 10-K · filed 2026-03-24 |
| 2024-09-30 | $14.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $16.06M derived: sum of 2 quarters · filed 2025-11-12 | -$60.62M 10-Q · filed 2025-11-12 | -$41.66M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$75.43M 10-Q · filed 2025-08-12 | -$56.47M derived: sum of 3 quarters · filed 2025-08-12 | -$36.33M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$76.68M 10-Q · filed 2025-05-13 | -$57.72M derived: sum of 2 quarters · filed 2025-05-13 | -$37.59M derived: sum of 3 quarters · filed 2025-05-13 | $32.56M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | $18.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $39.09M derived: sum of 2 quarters · filed 2025-03-18 | $109.25M derived: sum of 3 quarters · filed 2025-03-18 | $81.94M 10-K · filed 2025-03-18 |
| 2023-09-30 | $20.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $90.29M derived: sum of 2 quarters · filed 2024-11-12 | $62.99M 10-Q · filed 2024-11-12 | $32.81M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $70.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $42.85M 10-Q · filed 2024-08-14 | $12.67M derived: sum of 3 quarters · filed 2024-08-14 | -$66.05M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$27.30M 10-Q · filed 2024-05-14 | -$57.48M derived: sum of 2 quarters · filed 2024-05-14 | -$136.20M derived: sum of 3 quarters · filed 2024-05-14 | -$147.43M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$30.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$108.90M derived: sum of 2 quarters · filed 2024-03-21 | -$120.13M derived: sum of 3 quarters · filed 2024-03-21 | -$126.98M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$78.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$89.95M derived: sum of 2 quarters · filed 2023-11-14 | -$96.80M 10-Q · filed 2023-11-14 | -$105.12M derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$11.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$18.08M 10-Q · filed 2023-08-14 | -$26.40M derived: sum of 3 quarters · filed 2023-08-14 | -$33.22M derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$6.86M 10-Q · filed 2023-05-15 | -$15.17M derived: sum of 2 quarters · filed 2023-05-15 | -$21.99M derived: sum of 3 quarters · filed 2023-05-15 | -$65.36M derived: sum of 4 quarters · filed 2023-05-15 |
| 2021-12-31 | -$8.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$15.14M derived: sum of 2 quarters · filed 2023-03-30 | -$58.50M derived: sum of 3 quarters · filed 2023-03-30 | -$67.38M 10-K · filed 2023-03-30 |
| 2021-09-30 | -$6.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$50.19M derived: sum of 2 quarters · filed 2022-11-09 | -$59.06M 10-Q · filed 2022-11-09 | -$59.97M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | -$43.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$52.24M 10-Q · filed 2022-08-11 | -$53.15M derived: sum of 3 quarters · filed 2022-08-11 | -$53.89M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$8.88M 10-Q · filed 2022-05-11 | -$9.79M derived: sum of 2 quarters · filed 2022-05-11 | -$10.52M derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | -$910.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-22 | -$1.65M derived: sum of 2 quarters · filed 2022-03-22 | -$2.17M 10-K · filed 2022-03-22 | |
| 2020-09-30 | -$735.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | -$1.26M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$526.00K 10-Q · filed 2021-09-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |